“疗效数据很强,但毒性数据也非常强”。7月17日,FDA肿瘤药物咨询委员会(ODAC),拒绝批准葛兰素史克的 BCMA ADC 药物Blenrep用于二线联合治疗复发性或难治性多发性骨髓瘤。其中最引发关注的,便是其毒性问题。虽然ODAC的意见并不能完全左右FDA,但Blenrep的前景充满了新变数。原本,它大概率能成为ADC领域的一段佳话。2022年11月,Blenrep因确证性III期试验失败而...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.